Rana Minab1, Wei Bu2, Hanh Nguyen2, Abigail Wall3, Anton M Sholukh3, Meei-Li Huang3, Michael Ortego3, Elizabeth M Krantz3, Michael Irvine1, Corey Casper4, Jackson Orem5, Andrew T McGuire3,6, Jeffrey I Cohen2, Soren Gantt3,7. 1. University of British Columbia, Vancouver, Canada. 2. Laboratory of Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. 3. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 4. Infectious Disease Research Institute, Seattle, Washington, USA. 5. Uganda Cancer Research Institute, Kampala, Uganda. 6. Department of Global Health, University of Washington, Seattle, Washington, USA. 7. Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine, Montréal, Quebec, Canada.
Abstract
BACKGROUND: Epstein-Barr virus (EBV) infection is a major cause of malignancy worldwide. Maternal antibody is thought to prevent EBV infection because it is uncommon in early infancy. Maternal HIV infection is associated with an increased incidence of EBV infection in exposed infants, which we hypothesized results from impaired transfer of EBV-neutralizing maternal antibodies. METHODS: Among Ugandan infants followed for EBV acquisition from birth, we measured antibody binding to EBV glycoproteins (gp350, gH/gL) involved in B-cell and epithelial-cell entry, as well as viral neutralization and antibody-dependent cellular cytotoxicity (ADCC) activity in plasma samples prior to infection. These serologic data were analyzed for differences between HIV-exposed uninfected (HEU) and HIV-unexposed (HUU) infants, and for associations with incident infant EBV infection. RESULTS: HEU infants had significantly higher titers than HUU infants for all EBV-binding and neutralizing antibodies measured (P < .01) but not ADCC activity, which was similar between groups. No antibody measure was associated with a decreased risk of EBV acquisition in the cohort. CONCLUSIONS: Our findings indicate that in this cohort maternal antibody did not protect infants against EBV infection through viral neutralization. The identification of protective nonneutralizing antibody functions would be invaluable for the development of an EBV vaccine.
BACKGROUND: Epstein-Barr virus (EBV) infection is a major cause of malignancy worldwide. Maternal antibody is thought to prevent EBV infection because it is uncommon in early infancy. Maternal HIV infection is associated with an increased incidence of EBV infection in exposed infants, which we hypothesized results from impaired transfer of EBV-neutralizing maternal antibodies. METHODS: Among Ugandan infants followed for EBV acquisition from birth, we measured antibody binding to EBV glycoproteins (gp350, gH/gL) involved in B-cell and epithelial-cell entry, as well as viral neutralization and antibody-dependent cellular cytotoxicity (ADCC) activity in plasma samples prior to infection. These serologic data were analyzed for differences between HIV-exposed uninfected (HEU) and HIV-unexposed (HUU) infants, and for associations with incident infant EBV infection. RESULTS: HEU infants had significantly higher titers than HUU infants for all EBV-binding and neutralizing antibodies measured (P < .01) but not ADCC activity, which was similar between groups. No antibody measure was associated with a decreased risk of EBV acquisition in the cohort. CONCLUSIONS: Our findings indicate that in this cohort maternal antibody did not protect infants against EBV infection through viral neutralization. The identification of protective nonneutralizing antibody functions would be invaluable for the development of an EBV vaccine.
Authors: Erwan Piriou; Amolo S Asito; Peter O Sumba; Nancy Fiore; Jaap M Middeldorp; Ann M Moormann; Robert Ploutz-Snyder; Rosemary Rochford Journal: J Infect Dis Date: 2012-02-01 Impact factor: 5.226
Authors: Wei Bu; M Gordon Joyce; Hanh Nguyen; Dalton V Banh; Fiona Aguilar; Zeshan Tariq; Moh Lan Yap; Yusuke Tsujimura; Rebecca A Gillespie; Yaroslav Tsybovsky; Sarah F Andrews; Sandeep R Narpala; Adrian B McDermott; Michael G Rossmann; Yasuhiro Yasutomi; Gary J Nabel; Masaru Kanekiyo; Jeffrey I Cohen Journal: Immunity Date: 2019-04-09 Impact factor: 31.745
Authors: David R Martinez; Youyi Fong; Shuk Hang Li; Fang Yang; Madeleine F Jennewein; Joshua A Weiner; Erin A Harrell; Jesse F Mangold; Ria Goswami; George R Seage; Galit Alter; Margaret E Ackerman; Xinxia Peng; Genevieve G Fouda; Sallie R Permar Journal: Cell Date: 2019-06-13 Impact factor: 41.582
Authors: Joost Snijder; Michael S Ortego; Connor Weidle; Andrew B Stuart; Matthew D Gray; M Juliana McElrath; Marie Pancera; David Veesler; Andrew T McGuire Journal: Immunity Date: 2018-04-17 Impact factor: 31.745
Authors: Henrik Hjalgrim; Johan Askling; Klaus Rostgaard; Stephen Hamilton-Dutoit; Morten Frisch; Jin-Song Zhang; Mette Madsen; Nils Rosdahl; Helle Bossen Konradsen; Hans H Storm; Mads Melbye Journal: N Engl J Med Date: 2003-10-02 Impact factor: 91.245
Authors: Christina B Karsten; Yannic C Bartsch; Sally A Shin; Matthew D Slein; Howard M Heller; Kumaran Kolandaivelu; Jaap M Middeldorp; Galit Alter; Boris Julg Journal: PLoS Pathog Date: 2022-09-06 Impact factor: 7.464